Published in
Elsevier, Annals of Oncology, (31), p. S886, 2020
DOI: 10.1016/j.annonc.2020.08.1712
Links
Tools
1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI)
Journal article published in 2020 by
A. Dal Maso,
A. Ferro 
,
M. Lorenzi,
V. Polo,
D. Scattolin,
A. Del Conte,
E. Scoccia,
S. Frega,
L. Bonanno,
S. Indraccolo,
F. Calabrese,
V. Guarneri,
P. F. Conte,
G. Pasello
,
M. Lorenzi,
V. Polo,
D. Scattolin,
A. Del Conte,
E. Scoccia,
S. Frega,
L. Bonanno,
S. Indraccolo,
F. Calabrese,
V. Guarneri,
P. F. Conte,
G. Pasello
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 